Efficacy of two streptokinase formulations in acute myocardial infarction: A double-blind randomized clinical trial

Journal of Tehran University Heart Center

Volumn 4, Issue 1, 2009, Pages 29-34

  Salarifar, Mojtaba ^a   Sadeghian, Saeed ^a   Abbasi, Ali ^a   Davoodi, Gholamreza ^a   Amirzadegan, Alireza ^a   Hosseini, Seyed Kianoosh ^a   Paydari, Navid ^a   Biria, Aida ^a   Moemeni, Parisa ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Myocardial infarction; Streptokinase; Thrombolytic therapy

Indexed keywords

HEBERKINASA; STREPTOKINASE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; ANAPHYLAXIS; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; BODY MASS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART ARRHYTHMIA; HEART DEATH; HEART REINFARCTION; HEMODYNAMICS; HUMAN; HYPERTENSION; HYPERTHERMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; SIDE EFFECT; ST SEGMENT ELEVATION; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 77953391611     PISSN: 17358620     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Longstaff C, Thelwell C, Whitton C. The poor quality of streptokinase products in use in developing countries. J Thromb Haemost 2005;3:1092-1093.
2. Couto LT, Donato JL, de Nucci G. Analysis of five streptokinase formulations using the euglobulinlysis test and the plasminogen activation assay. Braz J Med Biol Res 2004;37:1889-1894.
3. Hernández L, Martinez Y, Quintana M, Besada V, Martinez E. Heberkinasa: recombinant streptokinase. Eur Heart J 2005;26:1691.
4. Lundergan CF, Reiner JS, McCarthy WF, Coyne KS, Califf RM, Ross AM. Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global utilization of streptokinase and t-PA for occluded coronary arteries. Am Coll Cardiol 1998;32:641-647.
5. Kucia AM, Stewart S, Zeits CJ. Continuous ST-segment monitoring: a non-invasive method of assessing myocardial perfusion in acute myocardial infarction. Eur J Cardiovasc Nurs 2002;1:41-43.
6. Davies CH, Ormerod OJ. Failed coronary thrombolysis. Lancet 1998;351:1191-1196.
7. Cundiff DK. Thrombolysis for acute myocardial infarction: drug review. Med Gen Med 2002;4:6.
8. Qasim A, Chauhan A, More RS. Failed thrombolysis in myocardial infarction. Int J Cardiol 2000;75:5-14.
9. Gaylani N, Davies S, Tovey J, Kinnarid T, Duly E, Buchalter MB. Systemic lytic state is not a predictor of coronary reperfusion in acute myocardial infarction. Int J Cardiol 1996;57:45-50.
10. Diwedi SK, Hiremath JS, Kerkar PG, Reddy KN, Manjunath CN, Ramesh SS, Prabhavati S, Dhobe M, Singh K, Bhusari P, Rao R. Indigenous recombinant streptokinase vs natural streptokinase in acute myocardial infarction patients: phase III multicentric randomized double blind trial. Indian J Med Sci 2005;59:200-207.
11. Clinical trial of China-made recombinant streptokinase in acute myocardial infarction. Collaborative Study Group on Thrombolysis with China-made recombinant streptokinase. Chin Med J (Engl) 1997; 110:50-52.
12. Multicenter, randomized, comparative study of recombinant vs. natural streptokinases in acute myocardial infarct (TERIMA). The TERIMA group investigators. Thrombolysis with recombinant streptokinase in acute myocardial infarct. Thromb Haemost 1999;82:1605-1609.
13. Llerena LD, Quirós JJ, Sainz B, Valdés JA, Zorio B, Villanueva LH, Filgueiras CE, Cabrera F, Echarte JC, Pérez del Todo JM, Guerrero I, López L, García EJ, Nadal B, Betancourt BY, Díaz-Rojo G, García AI, López-Saura P. Angiographic patency study of an albumin-free recombinant streptokinase formulation in acute myocardial infarction. J Pharm Pharm Sci 2004;7:372-377.
14. López HP, Cáceres Lóriga FM, Hernàndez KM, Sánchez HF, González Jimenez N, Marrero Mirayaga MA, López Saura P, Sigarroa F, Mendoza Y, Rodríguez Alvarez J. Thrombolytic therapy with recombinant streptokinase for prosthetic valve thrombosis. J Card Surg 2002;17:387-393.
15. Llerena LD, Cáceres-Lóriga FM, Betancourt BY. Recombinant streptokinase: evidences from clinical use. Eur Heart J 2005;26: 1448-1449.
16. The TERIMA Group of Investigators. TERIMA-2: national extension of thrombolytic treatment with recombinant streptokinase in acute myocardial infarct in Cuba. Thromb Haemost 2000;84:949-954.
17. Hermentin P, Cuesta-Linker T, Weisse J, Schmidt KH, Knorst M, Scheld M, Thimme M. Comparative analysis of the activity and content of different streptokinase preparations. Eur Heart J 2005;26:933-940.